COMMIT/CCS-2 major efficacy results End point Clopidogrel (n=22 958) (%) Placebo (n=22 891) (%) Relative risk reduction (%) p Death/ re-MI/stroke 9.3 10.1 9 2p=0.002 Death 7.7 8.1 7 2p=0.03 Re-MI 2.1 2.4 13 2p=0.02 Stroke 0.9 1.1 14 2p>0.1 Chen Z. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.

COMMIT/CCS-2 major bleeding Type of major bleed Clopidogrel (n) Placebo (n) Cerebral fatal 39 40 Cerebral nonfatal 16 15 Noncerebral fatal 36 37 Noncerebral nonfatal 46 Any major bleed 134 (0.58%) 124 (0.54%) Chen Z. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.

Primary composite end point (death/re-MI/stroke) by delay Hours to entry Clopidogrel (%) Placebo (%) 0-6 9.3 10.9 7-12 9.7 10.7 13-24 8.8 8.7 Chen Z. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.

Primary composite end point (death/ re-MI/stroke) by thrombolysis Lytic given Clopidogrel (%) Placebo (%) Yes 8.8 9.9 No 9.7 10.3 Chen Z. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.

Some of the major differences between COMMIT and CLARITY Characteristic COMMIT CLARITY Patients (n) 46 000 3500 Major end point Mortality/ re-MI/stroke Infarct patency Hours since MI symptom onset <24 <12 Age Up to 10O years Up to 75 years Loading dose given No Yes Thrombolysis Half of patients All patients Duration of clopidogrel treatment 2-3 weeks 2-3 days Follow-up PCI Very few patients Two thirds of patients Cannon C. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.